Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;20(6):823-830.
doi: 10.1038/s41397-020-0172-3. Epub 2020 May 28.

Association of HLA-DRB1*04:05 allele with drug-induced interstitial lung disease in Japanese population

Takuya Imatoh #  1 , Atsuhito Ushiki #  2 , Masao Ota #  3 , Michiko Ito  2 , Akihiro Sekine  4 , Taiki Yamashita  4 , Yoichi Mashimo  4 , Ryosuke Nakamura  1 , Kosuke Saito  1 , Yoshiro Saito  5 , Masayuki Hanaoka  6
Affiliations

Association of HLA-DRB1*04:05 allele with drug-induced interstitial lung disease in Japanese population

Takuya Imatoh et al. Pharmacogenomics J. 2020 Dec.

Abstract

Drug-induced interstitial lung disease (DILD) is a life-threatening adverse reaction. The Japanese population is more susceptible to DILD as compared with other populations, suggesting its pathogenesis could vary depending on ethnic genetic background. We conducted case-control studies to elucidate the association between DILD and HLA alleles in the Japanese. The 177 clinically diagnosed DILD patients and 3002 healthy controls for exploration and 55 DILD patients and 201 healthy controls for validation were genotyped for four HLA genes. HLA-DRB1*04:05 was significantly associated with DILD (corrected p = 0.014); this was also validated in the other set of patients/controls. Chemical drugs other than protein therapeutics showed this association (p = 1.7 × 10-4) . The Japanese population showed a higher HLA-DRB1*04:05 frequency than most other populations. In conclusion, HLA-DRB1*04:05 could be associated with DILD susceptibility in Japanese individuals, and its high general frequency may explain the high reported incidence of DILD in Japanese.

PubMed Disclaimer

References

    1. Kubo K, Azuma A, Kanazawa M, Kameda H, Kusumoto M, Genma A, et al. Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig. 2013;51:260–77. https://doi.org/10.1016/j.resinv.2013.09.001 . [Pubmed:24238235] - DOI - PubMed
    1. Amar RK, Jick SS, Rosenberg D, Maher TM, Meier CR. Drug-/radiation-induced interstitial lung disease in the United Kingdom general population: incidence, all-cause mortality and characteristics at diagnosis. Respirology. 2012;17:861–8. https://doi.org/10.1111/j.1440-1843.2012.02187.x . [Pubmed:22563933] - DOI - PubMed
    1. Nishimura T, Tada H, Nakagawa M, Teramukai S, Matsui S, Fukushima M. Lessons from gefitinib-induced interstitial lung disease in Japan: problems in approval, pharmacovigilance, and regulatory decision-making procedures. Pharm Pr (Granada). 2006;4:168–78. https://doi.org/10.4321/S1885-642X2006000400004 . [Pubmed:25214906] - DOI
    1. min JH, Lee HY, Lim H, Ahn MJ, Park K, Chung MP, et al. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemother Pharm. 2011;68:1099–109. https://doi.org/10.1007/s00280-011-1737-2 . [Pubmed:21913033] - DOI
    1. Fricke-Galindo I, LLerena A, López-López M. An update on HLA alleles associated with adverse drug reactions. Drug Metab Pers Ther. 2017;32:73–87. https://doi.org/10.1515/dmpt-2016-0025 . [Pubmed:28315856] - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources